D STATES PATENT AND TRADEMA

plicant:

Hagit ELDAR-FINKELMAN

Serial No.:

10/538,171

Filed:

June 9, 2005

For:

GLYCOGEN SYNTHASE KINASE-3 INHIBITORS

Group Art Unit: Not yet assigned

Docket: 29724

Attorney

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin O. Maynihan

Martin Moynihan

Registration No. 40,338

Dated: August 24, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/538,171 INFORMATION DISCLOSURE Filing Date June 9, 2005 STATEMENT BY APPLICANT First Named Inventor **ELDAR-FINKELMAN Hagit** Art Unit (use as many sheets as necessary) Not yet assigned **Examiner Name** Sheet of Attorney Docket Number 29724 U.S. PATENT DOCUMENTS Examiner Cite Document Number **Publication Date** Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Document Initials* No. Relevant Passages or Relevant Figures Appear Number-Kind Code² (if known) US-6,153,618 11-28-2000 Schultz et al. 2 US-6,057,117 02-2-2000 Harrison et al. 3 US-1,471,621 10-23-1923 McCord US-2,046,068 06-30-1936 4 Gray 5 US-3,193,159 06-6-1965 Swindler 6 US-4,186,646 05-5-1980 Martin 7 US-5,462,101 10-31-1995 Mouchmouchian

FOREIGN PATENT DOCUMENTS								
Examiner Cite No. 1		Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document Applicant of Cited Document Or Relevant Figures Application of the Applicatio		T		
	8	PCT WO 95/01376	01-12-1995	Comoglio et al.		Т		
	9	PCT WO 01/49709	07-12-2001	Eldar-Finkleman		Γ		
	10	PCT WO 02/24941	03-28-2002	Biondi et al.		I^-		
***	11	PCT WO 00/59206	05-5-2000	Mendlovic et al.				
	12	PCT WO 00/45237	03-3-2000	Cohen-Or et al.				
	13	PCT WO 00/74663	12-14-2000	Rosenthal et al.				
	14	PCT WO 98/16528	04-23-1998	Schultz et al.				
	15	PCT WO 2005/000192	06-6-2005	Eldar-Finkleman				
	16	PCT WO 97/33601	09-18-1997	Shaw et al.		Г		
	17	PCT WO 97/41854	11-13-1997	Klein et al.		F		
Examine	er	<u> </u>	1	Date	1			

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes

of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

1-1-1-1-1-1-1-1-1

Trainstation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



1 4 1005 Onder the Paperw			Approved for use throand Trademark Office: U.S. I	DEPARTN	MENT OF COMM			
Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of information unl						
		ostitute for form 1449A/PTO	Complete					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/538				
					9, 2005			
			First Named Inventor ELDA					
	~		Consum And Harit		LMAN Hagit			
		(use as many sheets as necessary)	Group Art Unit Examiner Name	Not ye	t assigned			
Choot	T	Of	Attorney Docket Number	29724				
Sheet		· · · · · · · · · · · · · · · · · · ·		29724				
		OTHER PRIOR ART – NON PATENT LITERA		- Cal				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the autem (book, magazine, journal, serial symposium, catalog, etc.) date			_2			
nitials	No.1	publisher, city and/or country where pu	blished.	ci(s),	T ²			
	18	Donella-Deana et al. "Dephosphorylation of Phosphope						
	1.0	(Protein Phosphatase 2B)", Eur. J. Biochem., 219(1-2):						
	19	Otaka et al. "Synthesis and Application of N-Box-L-2-A						
	117	4-,4-Difluorobutanoic Acid for Solid-Phase Synthesis of		10110)-				
		Phosphoserine Peptide Analogues", Tetrahedron. Lett.,						
	20			alie				
	20	Othaka et al. "Development of New Methodology for the		alized				
		α-Fluorophosphonates and Its Practical Application to t		1				
	-	Phosphopeptide Mimetics", Chem. Commun., 12: 1081						
	21	Pap et al. "Role of Glycogen Synthase Kinase-3 in the I	Phosphatidylinositol 3-					
		Kinase/Akt Cell Survival Pathway", J. Biol. Chem., 273	3: 19929-19932, 1998.					
	22	Phiel "Molecular Targets of Lithium Action", Annu. Re	v. Pharmacol. Toxicolog	gy,				
		41: 789-813, 2001.						
	23	Barrett et al. "Proteinase Inhibitors", Research Monographs in Cell and Tissue						
		Physiology, V-XXII,1986.	•					
	24	Roller et al. "Potent Inhibition of Protein-Tyrosine Phosphatase-1B Using the						
		Phosphotyrosyl Mimetic Fluoro-O-Malonyl Tyrosine (FOMT)", Bioorg. Med. Chem.						
		Lett., 8(16): 2149-2150, 1998.	Civily , Diooig. Mou. C	J				
	25	Rubinfeld et al. "Binding of GSK3Beta to the APC-Bet	a-Catenin Compley and	- 1				
		Regulation of Complex Assembly", Science, 272(5264)						
	26	Sambrook et al. "Molecular Cloning: A Laboratory Mai	0115					
	20		iluai, Cold Spring Haro	oui				
	127	Press, 2nd Ed., V-XXXII,1989. Schiller et al. "Synthesis for Side-Chain Cyclized Peptide Analogs on Solid						
	27			l				
		Supports", Int. J. Peptide Protein Res., 25: 171-177, 198						
	28	Shapiro et al. "Combained Fmoc-Alloc Strategy for A C						
		Phosphoserine Peptides: Preparation of Phosphorylation	n-Dependent Tau Antise:	ra",				
		Bioorg. Med. Chem., 5(1): 147-156, 1997.						
	29	Sherman et al. "Compatibility of Thioamides With Rev						
		and Conformational Analysis of Two Model Cyclic Pse						
		Thioamides as Backbone Modifications", Journal of the	American Chemical So	ciety,				
		112: 433-441, 1990.						
	30	Shulman et al. "Quantitation of Muscle Glycogen Synth	nesis in Normal Subjects	and				
		Subjects With Non-Insulin-Dependent Diabetes by 13C						
		Spectroscopy", New England Journal of Medicine, 322		-				
· -	31	Stambolic et al. "Lithium Inhibits Glycogen Synthase K		mics				
		Wingless Signalling in Intact Cells", Curr. Biol., 6: 166						
	32	ter Haar et al. "Structure of GSK-3 Beta Reveals A Prin			-			
	12	Mechanism", Nat. Struct. Biol., 8(7): 593-596, 2001.	nea i nospholytation					
	33		all I Am Conicto Sec	12.				
	33	Thomas "Excitatory Amino Acids in Health and Diseas	e, J. Aiii. Geriatr. Soc.,	45:				
	2.4	1279-1289, 1995.						
	34	Thorsett et al. "Dipeptide Mimics. Conformationally Re						
		Angiotensin-Converting Enzyme", Biochem. Biophys.	Res. Commun., 111(1):	166-				
		171, 1983.						
	35	Tong et al. "Activation of Glycogen Synthase Kinase-3						
		Platelet Activating Factor Mediates Migration and Cell	Death in Cerebellar Gra	nule				
	1	Neurons", Eur. J. Neurosci., 13: 1913-1922, 2001.						

PE			
SIPE 40	37	Welsh et a Slycogen Synthase Kinase-3 Is Rapidly Inactivate esponse to	
SEP 14 2003 E	31	Welsh et a lilycogen Synthase Kinase-3 Is Rapidly Inactivate esponse to Insulin and Sphorylates Eukaryotic Initiation Factor Eif-2B", Lochem. J., 294(Pt 3): 625-629, 1993.	
A TRADE AND	38	Wiemann et al. "Synthesis of Suitably Protected Hydroxymethylene Phosphonate- and 'Phosphat Phosphonate'-Analogues of Phosphoserine and Their Incorporation Into Synthetic Peptides", Tetrahedron, 56: 1331-1337, 2000.	
	39	Ye et al. "L-O-(2-Malonyl)Tyrosine: A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides", J. Med. Chem., 38(21): 4270-4275, 1995.	
	40	Eldar-Finkleman et al. "The Insulin Mimetic Action of Glycogen Synthase Kinase-3 Inhibitors", Diabetologia, 45(Suppl.2): A 70, 38th Annual Meeting for the European	
-	41	Association for the Study of Diabetes (EASD), Budapest, Hungary, 2002. Abstract. Plotkin et al. "Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3", Journal of Pharmacology and Experimental	
	42	Therapeutics, 305(3): 974-980, 2003. Leclerc et al. "Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Proteins Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's	
	43	Disease", The Journal of Biological Chemistry, 276(1): 251-260, 2001. Hotamisligil et al. "IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNT-α- and Obesity-Induced Insulin Resistance", Science, 271: 665-667,	
	44	1996. Tanti et al. "Serine/Threonine Phosphorylation of Insulin Receptor Substrate 1 Modulates Insulin Receptor Signaling", The Journal of Biological Chemistry, 269(8):	
	45	6051-6057, 1994. Fahraeus et al. "Inhibition of PRB Phosphorylation and Cell-Cycle Progression by A 20-Residue Peptide Derived From P16 CDKN2/INK4A", Current Biology, 6(1): 84-	
	46	91, 1996. Mitchell et al. "Heat-Stable Inhibitor Protein Derived Peptide Substrate Analogs: Phosphorylation by cAMP-Dependent and cGMP-Dependent Protein Kinases", Am. Chemical Soc., 1994.	
	47	Maniatis "Signal Transduction: Catalysis by A Multiprotein IkB Kinase Complex", Science, 278(5339): 818, 1997. Extract.	
	48	American Diabetes Association "Standards of Medical Care for Patients With Diabetes Mellitus", Diabetes Care, 17(6): 616-623, 1994.	
	49	Hawiger "Non-Invasive Intracellular Delivery of Functional Peptides", Curr. Opin. Chem. Biol., 3: 89-94, 1999.	
	50	Moreno et al. "Glycogen Synthase Kinase 3 Phosphorylation of Different Residues in the Presence of Different Factors: Analysis on TAU Protein", Mol.Cell.Biochem., 165(1):47-54, 1996. Tab.1.	
	51	Correll et al. "Inhibition of GSK3 Beta Mediates Cell Survival Society For Neuroscience Abstracts" 25(2): 1519, 1999. Abstract No. 605.8.	
	52	Oelrichs et al. "Unique Toxic Peptides Isolated From Sawfly Larvae in Three Continents", Toxicon, 37(3): 537-544, 1999. Fig. 3. Fiol et al. "Ordered Multisite Protein Phosphorylation. Analysis of Glycogen	
		Synthase. Kinase-3 Action Using Model Peptide Substrates", The Journal of Biological Chemistry, 265(11): 6061-6065, 1990. Vol.2: Abstract.	
	54	Barber et al. "Insulin Rescues Retinal Neurons From Apoptosis by A Phosphotidylinositol 3-Kinase/Akt-Mediated Mechanism That Reduces the Activation of Caspase-3", The Journal of Biological Chemistry, 276(350): 32814-32821, 2001.	
	55	Bijur et al. "Glycogen Synthase Kinese-3β Facilities Staurosporine- and Heat- Induced Apotosis", The Journal of Biological Chemistry, 275(11): 7583-7590, 2000.	
	56	Burke et al. "Potent Inhibition of Insulin Receptor Dephosphorylation by A Hexamer Peptide Containing the Phosphotyrosyl Mimetic F2Pmp", Biochemical and Biophysical Research Communications, 204(1): 129-134, 1994.	
	57	Burke et al. "4'-O[2(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhabitory Peptides", J. Med. Chem., 39: 1021-1027, 1996.	
	58	Burke et al. "Small Molecule Interactions With Protein-Tyrosine Phosphatase PTP1B and Their Use in Inhibitor Design", Biochemistry, 35: 15989-15996, 1996.	
	59	Chen et al. "Why Is Phosphonodifluoromethyl Phenylalanine A More Potent Inhibitory Moiety Than Phosphonomethyl Phenylalaline Towards Protein-Tyrosine	

IPE 40			
(38)			
EP 1 4 Tous B		Phosphata (%), Biochemical and Biophysical Research Communions, 216(3): 976-984,	
and the same of th	60	Cheng et al. "'Insulin-Like' Effects of Lithium Ion on Isolated Rat Adipocytes L.	
C TRABE		Stimulation of Glycogenesis Beyond Glucose Transport", Molecular and Cellular Biochemistry, 56: 177-182, 1983.	
	61	Chu et al. "Sequential Phosphorylation by Mitogen-Activated Protein Kinase and	
	"	Glycogen Synthase Kinase 3 Represses Transcriptional Activation by Heat Shock	
		Factor-1", The Journal of Biological Chemistry, 271(48): 30847-30857, 1996.	
	62	Cross et al. "Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by	
		Protein Kinase B", Nature, 378: 785-789, 1995.	
	63	Cross et al. "Selective Small-Molecule Inhibitors of Glycogen Synthase Kinase-3 Activity Protect Primary Neurons From Death", Journal of Neurochemistry, 77: 94- 102, 2001.	
	64	Crowder et al. "Glycogen Synthase Kinase-3ß Activity Is Critical for Neuronal Death Caused by Inhibiting Physpatidylinositol 3-Kinase or Akt But Not for Death Caused by Nerve Growth Factor Withdrawal", The Journal of the Biological Chemistry, 275(44): 34266-34271, 2000.	
	65	Dajani et al. "Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition", Cell, 105: 721-732, 2001.	
	66	Devlin et al. "Textbook of Biochemistry With Clinical Correlation", Wiley-Liss, 4th Ed., XVII-XXV, 1997.	
	67	Dugas et al. "Bioorganic Chemistry of the Amino Acids: Chemical Synthesis of Proteins", Springer Verlag, NY, P. 54-92, 1981.	<u>.</u>
	68	Eldar-Finkelman et al. "Expression and Characterization of Glycogen Synthase Kinase-3 Mutants and Their Effect on Glycogen Synthase Activity in Intact Cells", Proc. Natl. Acad. Sci. USA, 93(19): 10228-10233, 1996.	
	69	Eldar-Finkelman et al. "Phosphorylation of Insulin Receptor Substrate 1 by Glycogen Synthase Kinase 3 Impairs Insulin Action", Prc. Natl. Acad. Sci. USA, 94(18): 9660-9664, 1997.	
	70	Eldar-Finkelman et al. "Increased Glycogen Synthase Kinase-3 Activity in Diabetes-	
	71	and Obesity-Prone C57BL/6J Mice", Diabetes, 48(8): 1662-1666, 1999.	
	71	Fiol et al. "Formation of Protein Kinase Regognition Sites by Covalent Modification of Substrate. Molecular Mechanism for the Synergistic Action of Casein Kinase II	
	72	and Glycogen Synthase Kinase 3", J. Biol. Chem., 262(29): 14042-14048, 1987.	
	72	Fiol et al. "Phosphoserine as A Recognition Determinant for Glycogen Synthase Kinase-3: Phosphorylation of A Synthetic Peptide Based on the G-Component of	
		Protein Phosphatase-1", Arch. Biochem. Biophys., 267(2): 797-802, 1988.	
	73	Fiol et al. "A Secondary Phosphorylation of CREB341 at Ser129 Is Required for the	
		cAMP-Mediated Control of Gene Expression. A Role for Glycogen Synthase Kinase-3 in the Control of Gene Expression, J. Biol. Chem., 269(51): 32187-32193, 1994.	
	74	Fu et al. "Design and Synthesis of A Pyrodone-Based Phosphtyrosine Mimetic",	
		Bioorg. Med. Chem. Lett., 8(19): 2813-2816, 1998.	
	75	Gao et al. "Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2.4-(2-Malonyl)Phenylalanine as A Potent Phosphotyrosyl Mimetic", J.	
		Med. Chem., 43(5): 911-920, 2000.	
	76	Gething et al. "Cell-Surface Expression of Influenza Haemagglutinin From A Cloned DNA Copy of the RNA Gene", Nature, 293(5834): 620-625, 1981.	
	77	Groves et al. "Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics", Biochemistry, 37(51): 17773-17783, 1998.	
	78	Hallstrom et al. "Regulation of Transcription Factor Pdr1p Function by An Hsp70	
		Protein in Saccharomyces Cerevisiae", Mol. Cell Biol., 18(3): 1147-1155, 1998.	
	79	Hanger et al. "Glycogen Synthase Kinase-3 Induces Alzheimers Disease-Like Phosphorylation of Tau: Generation of Paired Helical Filament Epitopes and Neuronal Localisatoin of the Kinase", Neuroscience Letters, 147: 58-62, 1992.	
	80	Hawiger "Cellular Import of Functional Peptides to Block Intracellular Signaling",	
		Curr. Opin. Immunol., 9(2): 189-194, 1997.	
	81	He et al. "Glycogen Synthase Kinase-3 and Dorsoventral Patterning in Xenopus Embryos", Nature, 374(6523): 617-622, 1995.	
	82	Higashimoto et al. "Human P53 Is Phosphorylated on Serines 6 and 9 in Response to DNA Damage-Inducing Agents", J. Biol. Chem., 275(30): 23199-23203, 2000.	
	83	Klein et al. "A Molecular Mechanism for the Effect of Lithium on Development",	· · · · · · · · · · · · · · · · · · ·
L		The state of the s	

4 1005 E		Proc. Natl ad. Sci. USA, 93: 8455-8459, 1996.	
	84	Kole et al. Lotein-Tyrosine Phosphatase Inhibition by A Peptide Containing the Phosphotyrosyl Mimetic, L-O-Malonyltyrosine", Biochem. Biophys. Res. Commun.,	
RABE		209(3): 817-822, 1995.	
	85	Kole et al. "Specific Inhibition of Insulin Receptor Dephosphorylation by A	
		Synthetic Dodecapeptide Containing Sulfotyrosyl Residues as Phosphotyrosyl	
		Mimetic", Indian. J. Biochem. Biophys., 34(1-2): 50-55, 1997.	
	86	Latimer et al. "Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts	
		Fails to Induce Hyperphosphorylation of Transfected Tau", FEBS Lett., 365: 42-46,	
		1995.	
	87	Lucas et al. "Decreased Nuclear Beta-Catenin, Tahyperphosphorylation and	
	i	Neurodegeneration in GSK-3Beta Conditional Transgenic Mice", EMBO J., 20:27-	
		39, 2001.	
	88	Lovestone et al. "Alzheimer's Disease-Like Phosphorylation of the Microtubule-	
	1 00	Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian	
		Cells", Current Biology, 4: 1077-1086, 1995.	
	89	Mandelkow et al. "Tau as A Marker for Alzheimer's Disease", Trends Biochem. Sci.,	
		18(12): 480-483, 1983.	
	90	Mandelkow et al. "Glycogen Synthase Kinase-3 and the Alzheimer-Like State of	
		Micortubule-Associated Protein Tau", FEBS Letters, 314: 315-321, 1992.	
	91	Manji et al. "Lithium at 50: Have the Neuroprotective Effects of This Unique Cation	_
		Been Overlooked?", Biol. Psychiatry, 46(7): 929-940, 1999.	
	92	McKinsey et al. "Phosphorylation of the PEST Domain of IkappaBbeta Regulates the	
		Function of NF-KappaB/IkappaBbeta Complexes", J. Biol. Chem., 272(36): 22377-	
		22380, 1997.	
	93	Merrifield et al. "Solid Phase Peptide Synthesis. I. The Synthesis of A Tetrapeptide",	
	1 33		
	- 04	J. Am. Chem. Soc., 85: 2149-2154, 1963.	
	94	Mikol et al. "The Crystal Structures of the SH2 Domain of P56Ick Complexed With	
		Two Phosphonopeptides Suggest A Gated Peptide Binding Site", J. Mol. Biol.,	
		246(2): 344-355, 1995.	
	95	Morrison et al. "Organic Chemistry", Allyn and Bacon, 5th Ed., V-XXIV,1987.	
	96	Mulot et al. "PHF-Tau From Alzheimer's Brain Comprises Four Species on SDS-	
		PAGE Which Can Be Mimicked by In Vitro Phosphorylation of Human Brain Tau	
		by Glycogen Synthase Kinase-3 Beta", FEBS Lett., 349(3): 359-364, 1994.	
	97	Mulot et al. "Phosphorylation of Tau by Glycogen Synthase Kinase-3 Beta In Vitro	
		Produces Species With Similar Electrophoretic and Immunogenic Properties to PHF-	
		Tau From Alzheimer's Disease Brain", Biochem. Soc. Trans., 23(1): 45S, 1995.	
	98		
	98	Myers et al. "IRS-1 Activates Phosphatidylinositol 3'-Kinase by Associating With	
		SRC Homology 2 Domains of P85D", Proc. Natl. Acad. Sci. USA, 89(21): 10350-	
		10354, 1992.	
	99	Nicolaou et al. "Design and Synthesis of A Peptidomimeticemploying β-D-Glucose	
		for Scaffolding", Peptides, ESCOM, 1990.	
	100	Nikoulina et al. "Regulation of Glycogen Synthase Activity in Cultured Skeletal	
		Muscle Cells From Subjects With Type II Diabetes: Role of Chronic	
		Hyperinsulinemia and Hyperglycemia", Diabetes, 46(6): 1017-1024, 1997.	
	101	Nikoulina et al. "Potential Role of Glycogen Synthase Kinase-3 in Skeletal Muscle	
	101	Insulin Resitance of Type 2 Diabetes", Diabetes, 49(2): 263-271, 2000.	
	100		
	102	Nonaka et al. "Chronic Lithium Treatment Robustly Protects Neurons in the Central	
		Nervous System Against Excitotoxicity by Inhibiting N-Methyl-D-Aspartate	
		Rectpro-Mediated Calcium Influx", Proc. Natl. Acad. Sci. USA, 95: 2642-2647,	
		1998.	

Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.